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Introduction: Previous prognostic scoring systems for
malignant pleural mesothelioma (MPM) included patients
managed surgically and predated the use of pemetrexed.
We analyzed prognostic factors in a contemporary cohort of
patients with unresectable MPM who received pemetrexed-
based chemotherapy.
Methods: This single-institution analysis included patients
with MPM who were managed nonsurgically from 2000
to 2013. Variables correlated with overall survival (OS)
included sex, performance status (PS), asbestos exposure,
tumor laterality, histology, clinical stage, initial positron
emission tomography maximum standardized uptake
value, hemoglobin level, platelet count, lymphocyte count,
white cell and neutrophil counts, treatment type, and
clinical beneﬁt from treatment. OS was analyzed by the
Kaplan-Meier method, and signiﬁcance (p < 0.05) of prog-
nostic factors was analyzed by the log-rank test and Cox
regression.
Results: A total of 191 patients met the study criteria: me-
dian age 71 years (range 46–90), 147 men (77%), 128
epithelioid tumors (67%), and 157 cases of stage III or IV
MPM (82%). Median OS for all patients was 13.4 months.
According to a univariate analysis, histology (p < 0.001),
platelet count (450,000 versus>450,000,p<0.001), initial
PS (0–1 versus 2), maximum standardized uptake value
(8.1 versus >8.1, p ¼ 0.037), and lymphocyte counts (p ¼
0.019) were associated with OS. According to a multivariable
analysis, only histology, platelet count, and PS were inde-
pendent prognostic factors. Epithelioid histology, PS, and
elevated lymphocyte count at diagnosis were signiﬁcantly
associated with clinical beneﬁt from ﬁrst-line chemotherapy.
Conclusions: Our results conﬁrm the signiﬁcance of ele-
ments of the Cancer and Leukemia Group B and EuropeanOrganisation for Research and Treatment of Cancer prog-
nostic scoring systems, identify factors associated with
clinical beneﬁt from chemotherapy, and emphasize the
impact of histology and clinical beneﬁt of chemotherapy
on outcomes.
 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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Malignant pleural mesothelioma (MPM) is a rare tu-
mor arising from the mesothelial cells of the pleura and
is often related to asbestos exposure. The prognosis of
MPM is poor, with a median survival of 9 to 12 months
from diagnosis.1 Chemotherapy alone for advanced
stages, or in combination with surgery and/or radio-
therapy for resectable disease, is the mainstay of treat-
ment. For many patients with locally advanced disease
that is not surgically resectable because of tumor
invading the chest wall or the mediastinal structures,Journal of Thoracic Oncology Vol. 11 No. 2: 249-255
250 Billé et al Journal of Thoracic Oncology Vol. 11 No. 2treatment options are limited to palliative chemo-
therapy, radiotherapy, or best supportive care alone.
Since 2003, the combination of pemetrexed and cisplatin
has been the standard ﬁrst-line treatment based on the
results of a phase III trial showing almost a 3 month
improvement in median survival over treatment with
cisplatin alone.2 Chemotherapy beyond ﬁrst-line treat-
ment has no proven beneﬁt.3
Various prognostic factors for survival in MPM have
been described. The most signiﬁcant prognostic factor
remains histology: epithelioid mesothelioma is the sub-
type with the best prognosis.4–7 The tumor, node, and
metastasis staging system has been validated in several
large series, but the radiological assessment of tumor
extension is limited and can underestimate the real
extent of the tumor.5
Two groups created prognostic scores to better select
patients for more aggressive treatment: the Cancer and
Leukemia Group B (CALGB) and the European Organi-
sation for Research and Treatment of Cancer (EORTC).4,8
The CALGB study included 309 patients who had a
pathological diagnosis of mesothelioma and performance
status (PS) of 0 to 2 and had participated in one of seven
phase II trials between 1984 and 1994. Extent of pleural
disease, lactate dehydrogenase level higher than 500
UI/L, poor PS, platelet count higher than 400,000, non-
epithelial histology, and age older than 75 years were
negative prognostic factors for survival. When only pa-
tients for whom all factors were available (195 of 309)
were considered, pleural disease involvement and non-
epithelial histology were not prognostic factors in a
multivariate analysis. The best prognosis was in patients
younger than 49 years and with a PS of 0.4 The EORTC
study analyzed 204 patients who were enrolled in ﬁve
clinical trials between 1984 and 1993 and had a proven
diagnosis of mesothelioma; the study found that white
cell count (WBC), PS, certainty of histology, histological
subtype, and sex were independent prognostic factors.
Although both studies identiﬁed histology and perfor-
mance status as the two main prognostic factors in pa-
tients with mesothelioma, these analyses included
patients with a range of tumor stages at diagnosis, the
majority of whom underwent major surgery and whose
treatment predated the use of pemetrexed. Since the
routine use of pemetrexed as ﬁrst-line therapy began,
only one new prognostic index for overall survival (OS)
has been created; it is based on a retrospective analysis
of 283 patients who were treated with chemotherapy
alone in a clinical setting between 2007 and 2013. His-
tology, PS, stage (I–III versus IV), and pemetrexed-based
chemotherapy were independent prognostic factors for
survival; however, no factors were analyzed for associ-
ation with clinical beneﬁt from chemotherapy.8 We
therefore undertook this study to identify prognosticfactors in a more uniform, contemporary cohort of
nonsurgical patients treated with pemetrexed-based
regimens, as well as to identify factors that might
correlate with clinical beneﬁt from chemotherapy.Methods
Data Collection
We conducted a retrospective analysis of the medi-
cal records of patients with pathologically conﬁrmed
MPM who underwent evaluation and treatment be-
tween January 2000 and December 2013 at Memorial
Sloan Kettering Cancer Center (MSKCC). Patients with
peritoneal mesothelioma, patients treated at another
hospital, and patients lost to follow-up were excluded.
Patients who underwent pleurectomy with decortica-
tion or extrapleural pneumonectomy were excluded,
although patients who had a surgical procedure for
staging or diagnostic purposes or for palliation of a
pleural effusion were included. Patients who had
unresectable tumors at the time of surgery were also
included (Fig. 1).
Clinical records were analyzed for the following:
patient sex and age, documented exposure to asbestos,
history of smoking, method of diagnosis (computed
tomography [CT]-guided biopsy, surgical pleural biopsy,
or cytologic analysis), site of disease, performance status
(European Cooperative Oncology Group [ECOG] scale),
blood count at the time of the ﬁrst consultation, side of
disease, clinical staging, maximum standardized uptake
value (SUVmax) on positron emission tomography
(PET) before the treatment, histological subtype
(epithelioid, biphasic, or sarcomatoid), type of treatment
(chemotherapy and/or radiotherapy or supportive care),
chemotherapeutic agents, number of cycles and numbers
of different chemotherapy regimens, and whether an
exploratory thoracotomy had been performed. All tumor
specimens were centrally reviewed by an MSKCC
pathologist to conﬁrm the diagnosis and histological
subtype. All initial PET scans were performed before
treatment but at varying times after diagnosis, and some
were performed after talc pleurodesis.
Laboratory values used in the study were collected at
the time of the ﬁrst consultation at MSKCC. The normal
ranges of values for hemoglobin level, platelet count,
WBC, neutrophil count, and lymphocyte count were 13
to 17 g/dL, 160,000 to 400,000 per microliter, 4000 to
11,000 per microliter, 1500 to 8800 per microliter, and
500 to 5300 per microliter, respectively. For lymphocyte
counts, the median in this cohort was used as a cutoff.
For WBC and neutrophil count, the upper limit of normal
was used as a cutoff.
Some patients in this analysis responded to induction
chemotherapy or were considered clinically to have
Figure 1. Patient selection and reasons for exclusion.
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but were found to have unresectable tumor at surgery
because of involvement of the chest wall or the medias-
tinal organs.
Patients who were clinically stable andwho had stable
or responding disease as determined by serial imaging
studies (CT, PET, or both) after more than two cycles of
chemotherapy were considered to have received a clin-
ical beneﬁt from chemotherapy.Statistical Methods
All potential prognostic variables weremeasured at the
time of diagnosis. The end point of interest was OS, which
was analyzed using the Kaplan-Meier method and calcu-
lated from the date of diagnosis for baseline variables or
date of start of treatment for the treatment variables. The
log-rank test and Cox proportional hazards model were
used for univariate analyses. Baseline factors that were
associated with survival in univariate analysis (p < 0.10)
were tested for their independent role in a multivariate
analysis using the Cox proportional hazards model. Hazard
ratios and 95% conﬁdence intervals were calculated.
All statistical tests were two sided, and a p value less
than 0.05 was considered statistically signiﬁcant. Associa-
tions between baseline and treatment variables with clin-
ical beneﬁt from chemotherapy were tested using thechi-squared test for categorical variables. All analyses
were conducted using the software Packager, version 3.1.1
(R Development Core Team), including the “survival”
package.
Results
Of the 413 patients with MPM who were treated at
MSKCC between January 2000 and December 2013, 191
patients matched the inclusion criteria and were included
in the analysis. Patient characteristics are shown in
Table 1. The patients’ median age was 71 years, and 147
(77%)weremen. Themedian time between diagnosis and
treatmentwas 1.2months (range 0–68.2months). Despite
this large range, 78% of patients were treated within 3
months of diagnosis. One hundred sixty-one (84%) pa-
tients were diagnosed by thoracoscopic biopsy, 18 pa-
tients by CT guided biopsy, 4 by pleural ﬂuid cytology and
8 by openpleural biopsy. An exploratory thoracotomywas
performed on 52 patients, and 42 of them received neo-
adjuvant chemotherapy. At the time of surgery, all 52 pa-
tients were found to have unresectable disease due to
chest wall involvement (n ¼ 47) or mediastinal invasion
(n ¼ 5). In all, 177 patients received treatment with
chemotherapy, with 90% receiving pemetrexed, and 46
patients also underwent radiotherapy (n ¼ 46). Three
patients were treated with deﬁnitive radiotherapy only.
Table 1. Patient Characteristics (n¼191)
Characteristic N %
Age, median (range), y 71 (46–90)
Age, y
70 93 49
>70 98 51
Sex
Male 147 77
Female 44 23
Smoking historya
Never 92 48
Former 98 51
Asbestos exposurea
No 86 45
Yes 104 54
Side of disease
Right 116 61
Left 75 39
ECOG Performance Status
0-1 134 70
2-3 57 30
Platelet Countb
450,000 mm3 143 75
>450,000 mm3 46 24
Hemoglobin, median (range)c 12.5 (7.7–16.8)
White cell count, median (range)c 8.9 (3.4–23.6)
 ULN 146 76
> ULN 43 23
Neutrophil, median (range)c 6.25 (1.5–20.3)
 ULN 149 78
> ULN 37 19
Lymphocyte median (range) 1.4 (0.5–8.6)
 1.4 95 50
> 1.4 92 48
SUVmax, median (range) 8.1 (1.8–30.4)
8.1 72 38
>8.1 71 37
Unknown 48 25
Clinical stage
I-II 34 18
III 87 46
IV 70 37
Histology subtype
Epithelioid 128 67
Biphasic 20 10
Sarcomatoid 28 15
Non-speciﬁed 15 8
Treatment
Chemotherapy 131 69
Chemotherapy + radiotherapy 46 24
Radiotherapy 3 2
Palliative 11 6
(continued)
Table 1. Continued
Characteristic N %
No. of chemotherapy regimens
0 14 7
1 84 44
>1 93 49
Deﬁnitive radiotherapy 25 13
aFor one patient asbestos exposure and smoking history were both
unknown.
bTwo patients unknown platelet count
cHemoglobin level, neutrophil count, WBC, and/or lymphocyte
count were missing for two to ﬁve patients.
ECOG, Eastern Cooperative Oncology Group; ULN, upper limit of
normal; SUVmax, maximum standardized uptake value; WBC,
white blood count.
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The median follow-up time was 13.2 months.
Fourteen patients were still alive at the last available
follow-up, and the median OS was 13.4 months (95%
conﬁdence interval [CI]: 12.4–15.7). In univariateanalyses of OS (Table 2), factors associated with worse
prognosis included ECOG performance status of 2 or
higher, SUVmax greater than 8.1, platelet count higher
than 450,000 per mm3, a decreased number of lym-
phocytes, and biphasic or sarcomatoid histological
subtype. Elevated neutrophil count was only marginally
correlated with worse OS (p ¼ 0.060). Patients who
received only one line of chemotherapy and patients
who did not respond to chemotherapy also had
worse OS.
Patients with a good performance status (ECOG 0 or
1) had a better median OS and 1-year survival rate than
did patients with poor performance status (ECOG 2 or
3): 16.0 months (95% CI: 13.3–8.9) versus 10.1 months
(95% CI: 7.9–13.1) and 64% versus 42%, respectively.
Patients who had a lower SUVmax (8.1 versus >8.1)
showed a better median OS and 1-year survival rate:
15.8 months (95% CI: 13.2–20.9) versus 12.5 months
(95% CI: 11.1–15.7) and 65% versus 52%, respectively.
A platelet count of 450,000 per mm3 or less was
associated with a median OS of 15.2 months (95% CI:
13.3–17.9) and 1-year survival rate of 65%, whereas a
platelet count higher than 450,000 per mm3 was asso-
ciated with a median OS of 9.0 months (95% CI: 7.6–
11.6) and a 1-year survival rate of 32%. There was a
trend toward worse survival for elevated neutrophil
counts (p ¼ 0.060), but WBC was not associated with OS.
Patients with a decreased lymphocyte count showed a
worse prognosis (p ¼ 0.019). Patients with epithelioid
mesothelioma had a median OS of 17.0 months (95% CI:
14.3–19.4) with a 1-year survival rate of 69%, whereas
patients with biphasic or sarcomatoid mesothelioma
had a median OS of 9.6 months (95% CI: 7.5–11.4) and
1-year survival rate of 29%.
Patients who experienced a clinical beneﬁt from
chemotherapy had a better median OS than did pa-
tients who did not demonstrate clinical beneﬁt: 16.8
months (95% CI: 14.8–20.1) versus 6.5 months (95%
Table 2. Univariate Analysis of Overall Survival (N ¼ 191)
Characteristic
Median
OS, mo 95% CI p Value
Age, y 0.85
70 13.2 11.4–16.2
>70 13.4 12.2–18.7
Sex 0.45
Male 13.1 11.4–15.8
Female 14.7 12.6–20.1
Smoking historya 0.42
Never 13.3 12.2–17.4
Former 13.7 11.6–17.0
Asbestos exposurea 0.35
No 14.9 12.7–19.3
Yes 12.6 10.8–15.2
Side of disease 0.47
Right 13.1 11.4–16.2
Left 14.3 12.2–18.9
ECOG performance status <0.001
0–1 16.0 13.3–18.9
2–3 10.1 7.9–13.1
Platelet countb <0.001
450,000 per mm3 15.2 13.3–17.9
>450,000 per mm3 9.0 7.6–11.6
White cell count 0.13
ULN 13.8 12.4–17.4
>ULN 12.5 9.5–15.8
Neutrophil 0.060
ULN 14.7 13.0–17.4
>ULN 11.3 9.6–14.9
Lymphocyte 0.019
 1.4 11.4 9.8–14.5
>1.4 15.7 13.4–19.3
SUVmax 0.037
8.1 15.8 13.2–20.9
>8.1 12.5 11.1–15.7
Clinical stage 0.18
I–II 19.2 13.4–23.3
III 14.7 11.5–18.9
IV 12.0 9.5–13.8
Histology subtype <0.001
Epithelioid 17.0 14.3–19.4
Biphasic or sarcomatoid 9.6 7.5–11.4
Non-speciﬁed 9.9 7.9–38.3
Treatment 0.23b
Chemotherapya 10.6 9.1–13.0
Chemotherapy þ
radiotherapya
14.8 10.8–17.7
Radiotherapya 7.8 (6.0–NA)
Palliative 9.9 (9.2–NA)
Clinical beneﬁt from ﬁrst-line
chemotherapya
<0.001
No 6.5 5.4–8.5
Yes 16.8 14.8–20.1
(continued)
Table 2. Continued
Characteristic
Median
OS, mo 95% CI p Value
No. of chemotherapy regimensa 0.008
1 8.7 6.6–11.0
>1 14.2 12.1–16.8
Deﬁnitive radiotherapya 0.013
No 10.4 8.6–12.6
Yes 17.1 14.8–30.6
aFrom date of treatment start.
bChemotherapy versus chemotherapy and radiotherapy.
OS, overall survival; CI, conﬁdence interval; ECOG, Eastern Coop-
erative Oncology Group; ULN, upper limit of normal; NA, not
applicable.
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as well (70% versus 22%). Patients who received
more than one line of chemotherapy had a better
OS than did patients who received only one line ofchemotherapy, with a median OS of 14.2 months (95%
CI: 12.1–16.8) versus 8.7 months (95% CI: 6.6–11.0)
months, and their 1-year survival rate was better as
well: 60% versus 37%. Among those who demon-
strated clinical beneﬁt from ﬁrst-line chemotherapy
(n ¼ 99), 60 (61%) received a second line of chemo-
therapy. Patients who received deﬁnitive radiotherapy
(n ¼ 25) showed signiﬁcant improvement in survival
(p ¼ 0.013) compared with patients who were treated
with only chemotherapy: median OS 17.1 months
(95% CI: 14.8–30.6) versus 10.4 months (95% CI:
8.6–12.6).
In a multivariate analysis, only histological subtype,
platelet count, and PS were independent prognostic
factors for OS (Table 3). The greatest hazard ratios were
seen for sarcomatoid mesothelioma (a 3.00 times higher
risk for death than for epithelioid mesothelioma), for
platelet count higher than 450.000 per mm3 (2.02 times
greater than for a lower platelet count) and for patients
with an ECOG PS of 2 or higher (1.88 times greater than
for a good PS).
Response to Chemotherapy and Radiation
A total of 160 patients received pemetrexed-based
chemotherapy, 14 received pemetrexed alone, and the
rest received pemetrexed in combination with cisplatin
or carboplatin (n ¼ 90 and n ¼ 55) or gemcitabine (n ¼
1). There was a trend toward association between
receipt of deﬁnitive radiotherapy and OS (p ¼ 0.081), in
which case patients who received radiotherapy showed a
1-year OS of 61% versus 44% for patients who did not
receive radiotherapy.
There was no association between clinical beneﬁt
from chemotherapy and smoking history. Patients with
good PS had a clinical beneﬁt rate of 64% compared
with 36% in patients with poor PS (p ¼ 0.001); 63%
percent of patients with epithelioid mesothelioma and
45% of patients with the sarcomatoid subtype demon-
strated clinical beneﬁt from ﬁrst-line chemotherapy and
Table 3. Multivariate Analysis (N ¼ 140)
Characteristic HR 95% CI p Value
Histologic diagnosis (biphasic or
sarcomatoid vs. epithelioid)
2.96 1.91–4.57 <0.001
Platelet count (>450,000 vs.
450,000)
2.09 1.33–3.35 0.002
Performance status (2–3 vs. 0–1) 1.83 1.23–2.74 0.003
SUVmax (>8.1 vs. 8.1) 1.17 0.80–1.71 0.41
Neutrophil count (>ULN vs. ULN) 1.27 0.82–1.99 0.29
Lymphocyte count (>1.4 vs. 1.4) 0.78 0.54–1.12 0.17
HR, hazard risk; CI, Conﬁdence interval; SUVmax, maximum stan-
dardized uptake value; ULN, upper limit of normal.
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Elevated lymphocyte count (>1400 cells per microliter)
was associated with clinical beneﬁt from chemotherapy
(p ¼ 0.010): 67% of patients with a lymphocyte count
higher than 1400 cells per microliter versus 46% of
patients with a lymphocyte count less than 1400 cells
per microliter demonstrated clinical beneﬁt and received
more than two cycles of chemotherapy. Sex, clinical
stage, SUVmax, and platelet count were not associated
with clinical beneﬁt from chemotherapy.
Discussion
Prognostic factors, such as those in the CALGB and
EORTC indices, have been analyzed previously to select
patients with MPM who have a favorable prognosis
and could tolerate and potentially beneﬁt from a more
aggressive combined modality treatment. However, prior
analyses included mainly selected patients in clinical
trials, patients undergoing extensive surgery, and pa-
tients receiving chemotherapy before the use of peme-
trexed became routine. Our study, which examined a
relatively uniform group of patients with unresectable
disease who received predominantly pemetrexed-based
therapy, conﬁrms that some elements of the CALGB
and EORTC prognostic scoring systems correlate with
survival in this patient population. We also identiﬁed
several factors associated with clinical beneﬁt from
pemetrexed-based chemotherapy.
As in previous studies, we conﬁrmed the importance
of the histology on OS.4,5,7,8 Patients with biphasic and
sarcomatoid mesothelioma had a poorer prognosis than
did patients with epithelioid mesothelioma. Of note,
because these patients did not undergo extensive surgical
resections, histological subtypes were determined on
the basis of small biopsy samples, and therefore, a tumor
identiﬁed as epithelioid might in fact have been a tumor
with mixed histological ﬁndings had the sample been
larger. ECOG PS and platelet count were also conﬁrmed to
be independent prognostic factors for survival in multi-
variate analysis. Our study did not conﬁrm the importance
of sex and age as prognostic factors; however, the analysesmay have been confounded by the small numbers of
young patients and females in our study population.
An additional limitation associated with prognostic
analyses of patients with MPM is the inaccuracy of
clinical staging.5 Precise measurements of extent of dis-
ease and invasion are limited radiographically. In addi-
tion, prior analyses were limited by the ways in which
stages were grouped together. Whereas the EORTC
separated stage I and II from III and IV, the more recent
analysis including patients treated with pemetrexed-
based therapy have compared stages I through III with
stage IV. By focusing only on patients with unresectable
disease, our analysis minimizes the issues related to
clinical staging.
We also examined the impact of blood cell counts and
found platelet count to be an independent prognostic
factor for survival. In univariate analysis, an elevated
lymphocyte count and decreased neutrophil count were
also associated with a better prognosis, thus implicating
the importance of the immune system for inhibiting tu-
mor growth. PET ﬁndings have been routinely used as
prognostic factors in cases involving other solid cancers,
but its role in clinical staging of patients with mesothe-
lioma has been incompletely established, in part because
of its limited sensitivity for T and N staging.9,10 Some
studies have shown conﬂicting results regarding the
predictive value of SUVmax.11,12 Our analysis of PET
imaging, which demonstrated that SUVmax was signiﬁ-
cant only in univariate analysis, was limited by two
factors: some patients with MPM had undergone pleu-
rodesis before having a PET scan, and not all the scans
were performed at the same center.
In the CALGB study, there was no difference between
different chemotherapy agents in terms of survival;
however, chemotherapy treatment was a predictive
factor for survival in a recent published model in elderly
patients.13 In this study, more than 90% of our patients
received a pemetrexed-based ﬁrst-line chemotherapy,
and those who received more than two cycles of chemo-
therapy, if clinically stable, demonstrated improved
survival. In our study, patients who received clinical
beneﬁt from ﬁrst-line chemotherapy showed a 10-month
improvement in median OS. Unlike the study by Kataoka
et al.,14 our study also evaluated factors associated
with a clinical beneﬁt from chemotherapy. Better PS,
epithelioid histology, and elevated lymphocyte count
were associated with clinical beneﬁt from ﬁrst-line
chemotherapy. Patients who underwent second-line
chemotherapy demonstrated better median OS than did
patients who only received one line of chemotherapy.
This ﬁnding might be confounded by the fact that patients
who lived longer were more likely to have received
additional chemotherapy. Finally, the analysis of radia-
tion therapy in our series did not reveal an association
February 2016 Unresectable Malignant Pleural Mesothelioma 255with better OS than that resulting from treatment with
chemotherapy alone.
Despite some limitations and confounding factors,
our analysis expands on prior studies of prognostic
factors in MPM. In particular, we identiﬁed that
increased lymphocyte count is associated with clinical
beneﬁt from ﬁrst-line chemotherapy and that platelet
count, histology, and initial PS are prognostic for survival
in a multivariate analysis. Although future studies eval-
uating the biology of MPM as well as the prognostic
value of measurements of tumor volume may improve
our ability to select therapy, our results easily deﬁne
measurable clinical factors that can help direct patient
treatment.
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